

Standardised report for CT: Follow-up of NEN

Indication

Location of the primary tumor (if known):

Tumor-predisposition syndrome:

If yes:

Histology:

Type:

Differentiation:

Grade:

Clinical symptoms:

If yes, please describe:

Treatment:

Type (including watch and wait):

Date of start of last treatment:

Date of NADIR:

Technique

Iodinated-based contrast agent injection:

If yes, name:

Quantity: ml

Type of acquisition:

Qualitative assessment

Description of tumor burden: anatomical location and number of lesions: primary tumor (if present) and metastatic lesions:

% of liver involvement:

Changes in tumor phenotype:

Decrease of vascularisation:

Presence of necrosis:

Quantitative assessment (according RECIST 1.1)

Size assessment according to RECIST 1.1 Criteria

Target lesions:

Target 1: Location: Size: mm

Target 2: Location: Size: mm

Target 3: Location: Size: mm

Target 4: Location: Size: mm

Target 5: Location: Size: mm

Sum size: % of change:

Target lesion response:

Non target lesions (location, evaluation (CR, PD, non PD non CR):

New lesions (description with anatomical location):

Overall response (CR, PR, SD, PD):

Viable tumor assessment according to mRECIST (applicable for TACE treatment)

Target 1: Location: Size: mm

Target 2: Location: Size: mm

Target 3: Location: Size: mm

Target 4: Location: Size: mm

Target 5: Location: Size: mm

Sum size: % of change:

mRECIST response:

Vascular response assessment according to CHOI criteria (applicable for research and targeted therapies treatment)

Target 1: Location: Density (UH):

Target 2: Location: Density (UH):

Target 3: Location: Density (UH):

Target 4: Location: Density (UH):

Target 5: Location: Density (UH):

Sum of density: % of change:

CHOI criteria response:

Other relevant findings

Free text:

Conclusions

Free text: